Boehringer Ingelheim, a global leader in animal health, and Invetx, a Boston-based pioneer in protein-based therapeutics for animal health, announce that they have entered into a collaboration agreement to develop novel, species-specific monoclonal antibody biotherapeutics targeting a wide range of diseases in the veterinary species, initially focused on dogs and cats.
For each selected disease target, Invetx will apply its unique platform to the discovery and optimization of best-in-class candidates and Boehringer Ingelheim will advance these therapies through clinical and regulatory development to bring them to market. Terms of the agreement were not disclosed.
“This partnership is a prime example of Boehringer Ingelheim’s commitment to address unmet needs in the rapidly growing animal health market,” shared Eric Haaksma, head of Global Innovation, Animal Health at Boehringer Ingelheim. “We were drawn to working with Invetx because of the company’s cutting-edge discovery platform, optimization technologies and antibody expertise. Together, we will leverage innovation to discover breakthrough scientific advancements to improve animal health.”
Today, monoclonal antibodies are currently used in the treatment of many human diseases. The therapy is a form of immunotherapy that uses monoclonal antibodies (mAbs) to bind monospecifically to certain cells or proteins, mimicking the body’s own natural response to attack those cells. Leveraging the technology in animal health creates great potential to address unmet needs.
Invetx’s fully integrated platform encompassing discovery, product development and commercial manufacturing sets a new standard for veterinary biotherapeutics. By leveraging validated technologies in human biotech and optimizing them for veterinary application, Invetx can generate differentiated antibodies against a wide range of targets to treat a variety of chronic and serious diseases in animals.
“We are thrilled to partner with global animal health leader Boehringer Ingelheim, using our unique discovery platform to deliver fully species-specific, optimized and half-life extended biotherapeutics,” said Juergen Horn, PhD, chief executive officer of Invetx. “These programs will complement our own proprietary portfolio and strengthen our position as a leader in creating novel, transformative and best-in-class therapies for veterinary patients.”